NMRA.US Neumora Therapeutics, Inc.

Healthcare Pharmaceuticals USA Stocks
0.3695 USD
Close of Nov 17, 2026
0.3150 3.65
Market cap
USD 69.4M
P/E
-
P/B
1.81x
ROE
-433.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is NMRA.US undervalued?

Graham number

The Graham number of Neumora Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Neumora Therapeutics, Inc. fundamental analysis

No fundamental analysis for Neumora Therapeutics, Inc. yet.

Neumora Therapeutics, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Neumora Therapeutics, Inc.

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients …

Full company profile